Purchase Short-Term Access

Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs

Peter W. de Leeuw, MD

Annals of Internal Medicine 2013;158:JC7. doi:10.7326/0003-4819-158-6-201303190-02007

Purchase Online access to this article for 24 hours

Annals of Internal Medicine

Forgot Your Password?

to gain full access to the content and tools.

Learn more about subscription options

Forgot your password?

Enter your username and email address. We'll send you a reminder to the email address on record.

Username* (Required)

Email Address* (Required)